Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT02989025 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Progesterone to Enhance the Efficacy and Success of Expectantly Managed Preterm Severe/Superimposed Preeclampsia

Study acronym: PROGRESS
StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Re-verified, no change to tracked fieldsv12
  2. Lead sponsor: Babbette Lamarca to University of Mississippi Medical Center
    • Primary and study completion dates: Jan 31, 2026 to Jan 31, 2027
    • Site contact updated
    v11
  3. Primary and study completion dates: Jan 31, 2024 to Jan 31, 2026v10
  4. Site contact updated
    • Study arms: 1 to 2
    v9
  5. Primary completion date: Jan 30, 2022 to Jan 31, 2024
    • Study completion date: Jan 31, 2022 to Jan 31, 2024
    v8
Show 6 earlier versionsHide 6 earlier versions
  1. Primary completion date: Dec 31, 2020 to Jan 30, 2022
    • Study completion date: Dec 31, 2021 to Jan 31, 2022
    v7
  2. Phase: Phase 3 to Phase 2
    • Primary completion date: Jan 31, 2020 to Dec 31, 2020
    • Study completion date: Jan 31, 2020 to Dec 31, 2021
    • Site contact updated
    v6
  3. Eligibility criteria shortened, about 13 wordsv5
  4. Primary and study completion dates: Jan 31, 2018 to Jan 31, 2020v4
  5. Trial status: Not Yet Recruiting to Recruiting
    • Site details revised
    v3
  6. Enrollment target: 30 to 60v2 Show 8 more changesShow less
    • Start date: Dec 2016 to May 22, 2017
    • Primary and study completion dates: Sep 2017 to Jan 31, 2018
    • Interventions: 17 OHPC (Drug), Control/Normal Saline (Drug) to 17 OHPC (Drug)
    • Eligibility criteria revised
    • Secondary endpoints: details revised at 1 of 1 entry
    • Study description expanded, about 18 words
    • Study title revised
    • Study arms: 2 to 1
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this study is to learn if giving 17-hydroxyprogesterone caproate (17 OHPC) to mothers with preeclampsia diagnosed before 34 weeks gestation improves mother and baby outcomes.
Trial Details
NCT Number NCT02989025
Lead Sponsor University of Mississippi Medical Center
Conditions
(from sponsor)		 Pregnancy, Preeclampsia (PE)
Related terms Pre-Eclampsia
Enrollment 60 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov